Dan Calugaru

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11281776/publications.pdf

Version: 2024-02-01

90	415	1051969 10	1113639 15
papers	citations	h-index	g-index

90	90	90	96
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comment on: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema. International Journal of Ophthalmology, 2022, 15, 681-682.	0.5	0
2	Intraocular pressure modifications in patients with acute central/hemicentral retinal vein occlusions. International Journal of Ophthalmology, 2021, 14, 931-935.	0.5	4
3	Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study. International Journal of Ophthalmology, 2021, 14, 1127-1128.	0.5	0
4	Macular atrophy development in neovascular age-related macular degeneration. European Journal of Ophthalmology, 2020, , 112067212094873.	0.7	0
5	Correspondence. Retina, 2020, 40, e39-e41.	1.0	0
6	Switching from ranibizumab and aflibercept to bevacizumab therapy in neovascular age-related macular degeneration patients. European Journal of Ophthalmology, 2020, 30, NP1-NP2.	0.7	0
7	Comment on â€œIntravitreal conbercept injection for neovascular age-related macular degenerationâ€• International Journal of Ophthalmology, 2020, 13, 362-364.	0.5	3
8	Comment on â€œMicrovascular changes after conbercept therapy in central retinal vein occlusion analyzed by optical coherence tomography angiographyâ€• International Journal of Ophthalmology, 2020, 13, 848-850.	0.5	2
9	Comment on "Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study". International Journal of Ophthalmology, 2020, 13, 1678-1680.	0.5	0
10	Comment on â€œAnatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort studyâ€• International Journal of Ophthalmology, 2020, 13, 1678-1680.	0.5	0
11	Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. American Journal of Ophthalmology, 2019, 205, 200-201.	1.7	2
12	Re: Chan etÂal: Disorganization of Retinal Inner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion. (Ophthalmol Retina. 2019;3:83-92). Ophthalmology Retina, 2019, 3, e9.	1.2	0
13	Re: Bailey etÂal: Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial (Ophthalmology. 2019;126:75â€“86). Ophthalmology, 2019, 126, e71-e72.	2.5	3
14	Ischemic retinal vein occlusion: Characterizing the more severe spectrum of retinal vein occlusion. Survey of Ophthalmology, 2019, 64, 440-441.	1.7	2
15	Re: Berry etÂal: Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion (Ophthalmol Retina. 2018;2:1125-1132). Ophthalmology Retina, 2019, 3, e1.	1.2	3
16	Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 241-242.	1.0	5
17	Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study. American Journal of Ophthalmology, 2019, 198, 262-263.	1.7	7
18	Management of the open angle glaucoma in patients with central/hemicentral retinal vein occlusions. International Journal of Ophthalmology, 2019, 12, 436-441.	0.5	2

#	Article	IF	Citations
19	Comment on â€œCorrelation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusionâ€• International Journal of Ophthalmology, 2019, 11, 695-696.	0.5	1
20	Comment on "The thickness and volume of the choroid, outer retinal layers and retinal pigment epithelium layer changes in patients with diabetic retinopathy". International Journal of Ophthalmology, 2019, 12, 1366-1368.	0.5	1
21	Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1209-1210.	1.0	5
22	Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1035-1037.	1.0	4
23	Re: Khurana etÂal.: Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study (Ophthalmol Retina . 2017). Ophthalmology Retina, 2018, 2, e5-e6.	1.2	3
24	Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. Seminars in Ophthalmology, 2018, 33, 318-319.	0.8	3
25	Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1353-1354.	1.0	6
26	Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 221-223.	1.0	5
27	Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 233-235.	1.0	4
28	Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome. American Journal of Ophthalmology, 2018, 186, 164-165.	1.7	7
29	Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 627-629.	1.0	3
30	Correspondence. Retina, 2018, 38, e69-e71.	1.0	0
31	Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. American Journal of Ophthalmology, 2018, 196, 208-209.	1.7	5
32	Re: Li etÂal.: Long-term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor (Ophthalmol Retina. 2018;2:550â€“557). Ophthalmology Retina, 2018, 2, e13-e14.	1.2	4
33	Comments to: Restoration of photoreceptors in eyes with diabetic macular edema. European Journal of Ophthalmology, 2018, 28, 132-133.	0.7	2
34	Vision Outcomes Following Antiâ€“Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. American Journal of Ophthalmology, 2018, 193, 253-254.	1.7	5
35	What We Have Learned From the Ocular Hypertension Treatment Study. American Journal of Ophthalmology, 2018, 192, 248-249.	1.7	1
36	Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 2269-2270.	1.0	4

#	Article	IF	Citations
37	The fate of eyes with wet AMD beyond 4Âyears of anti-VEGF therapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1551-1552.	1.0	3
38	Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 160-160.	0.4	2
39	Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management. International Journal of Ophthalmology, 2018, 11, 1173-1178.	0.5	4
40	Comment on â€œManagement strategies in malignant glaucoma secondary to antiglaucoma surgeryâ€. International Journal of Ophthalmology, 2018, 11, 1433-1434.	0.5	2
41	Comment on â€œAssessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degenerationâ€. International Journal of Ophthalmology, 2018, 11, 1884-1886.	0.5	2
42	Comment on â€œIntravitreal dexamethasone implants for diabetic macular edemaâ€. International Journal of Ophthalmology, 2018, 11, 2029-2032.	0.5	3
43	Romanian ophthalmologists in the renowned ophthalmic journals worldwide. Romanian Journal of Ophthalmology, 2018, 62, 260-269.	0.4	0
44	Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 211-212.	1.0	3
45	Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2017, 174, 181-182.	1.7	12
46	Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting. American Journal of Ophthalmology, 2017, 174, 185-186.	1.7	10
47	Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion. American Journal of Ophthalmology, 2017, 176, 257-258.	1.7	7
48	Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1455-1457.	1.0	3
49	Comments to: Visual and Anatomic Outcomes after Conversion to Aflibercept in Neovascular Age-Related Macular Degeneration: 12-Month Results. European Journal of Ophthalmology, 2017, 27, e134-e134.	0.7	3
50	Correspondence. Retina, 2017, 37, e78-e79.	1.0	2
51	Correspondence. Retina, 2017, 37, e84-e86.	1.0	5
52	Comments to: Ranibizumab for Persistent Diabetic Macular Edema after Bevacizumab Treatment. European Journal of Ophthalmology, 2017, 27, e104-e105.	0.7	4
53	Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Canadian Journal of Ophthalmology, 2017, 52, 137.	0.4	4
54	Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1043-1044.	1.0	5

#	Article	IF	Citations
55	Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1451-1452.	1.0	10
56	Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. American Journal of Ophthalmology, 2017, 177, 235-236.	1.7	3
57	Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 427-428.	1.0	6
58	Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion. American Journal of Ophthalmology, 2017, 184, 190-191.	1.7	15
59	High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2067-2068.	1.0	6
60	Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2073-2075.	1.0	3
61	Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial. American Journal of Ophthalmology, 2017, 182, 204-205.	1.7	6
62	Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2017, 173, 145-146.	1.7	13
63	Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting. American Journal of Ophthalmology, 2017, 174, 175-176.	1.7	10
64	Correspondence. Retina, 2017, 37, e108-e110.	1.0	2
65	Correspondence. Retina, 2017, 37, e139-e141.	1.0	3
66	Comments to: Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal. European Journal of Ophthalmology, 2017, 27, e190-e191.	0.7	3
67	Comments to: Clinical Experience of Switching Anti-VEGF Therapy from Ranibizumab to Aflibercept in Age-Related Choroidal Neovascularization. European Journal of Ophthalmology, 2017, 27, e107-e108.	0.7	4
68	Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 280-280.	0.4	3
69	Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 528-529.	0.4	4
70	Comment on â€œPredictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusionâ€. International Journal of Ophthalmology, 2017, 10, 1481-1482.	0.5	3
71	Comments To: Response to Bevacizumab after Treatment with Aflibercept in Eyes with Neovascular AMD. European Journal of Ophthalmology, 2016, 26, e138-e138.	0.7	3
72	Correspondence. Retina, 2016, 36, e9-e10.	1.0	0

#	Article	IF	Citations
73	Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. American Journal of Ophthalmology, 2016, 169, 291-292.	1.7	2
74	Comments to: Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema. European Journal of Ophthalmology, 2016, 26, e171-e172.	0.7	7
75	Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated With Ozurdex Trial. American Journal of Ophthalmology, 2016, 170, 244-245.	1.7	6
76	Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. American Journal of Ophthalmology, 2016, 168, 290-291.	1.7	14
77	Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2477-2478.	1.0	4
78	Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmologica, 2016, 94, e80-1.	0.6	5
79	Correspondence. Retina, 2016, 36, e83-e84.	1.0	1
80	Correspondence. Retina, 2016, 36, e112-e113.	1.0	2
81	Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study:) Tj ETQq1 1 0.784314 rgBT /Ove Ophthalmology, 2016, 254, 1023-1024.	1.0	6
82	Pro-permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; The Ozurdex for Retinal Vein Occlusion (ORVO) Study. American Journal of Ophthalmology, 2016, 161, 215-216.	1.7	5
83	Central retinal vein occlusion in a young adult Case report. Romanian Journal of Ophthalmology, 2016, 60, 120-124.	0.4	0
84	Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions. Romanian Journal of Ophthalmology, 2016, 60, 145-152.	0.4	0
85	Correspondence. Retina, 2015, 35, e59-e61.	1.0	4
86	Re: Yeh etÂal.: Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology (Ophthalmology) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 217	2.8	7
87	Intravitreal Bevacizumab in Acute Central/Hemicentral Retinal Vein Occlusions: Three-Year Results of a Prospective Clinical Study. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 78-86.	0.6	58
88	Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3ÂGALILEOÂStudy. American Journal of Ophthalmology, 2015, 159, 607-608.	1.7	10
89	Letter to the Editor: Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 994-994.	0.4	4
90	Prevention of Neovascular Glaucoma. Ophthalmology, 2013, 120, 1507-1508.e2.	2.5	13